Related Experiment Video
Updated: Nov 17, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
The presence of SARS-CoV2 antibodies in MS patients
Asya I Wallach1, Mary Ann Picone1
1Alfiero and Lucia Palestroni MS Comprehensive Care Center at Holy Name Medical Center, 718 Teaneck Rd., Teaneck, NJ 07666, USA.
Background:
The COVID-19 pandemic has raised novel concerns for people living with MS regarding their safety.
Methods:
Observational study of patients at a single comprehensive community MS center.
Results:
48 patients with MS were suspected of developing COVID-19 March to May 2020; 2 died. Of the remainder, 17 were tested for COVID-19 antibodies as part of routine care. Average age of this subgroup was 49.8y ± 11.3 (age range 32-67), 76% female. 65% were treated with an anti-CD20 drug, 12% untreated, and 6% each received glatiramer acetate, interferon, natalizumab, or teriflunomide. 59% of patients were antibody negative.
Conclusions:
The low incidence of SARS CoV2 antibodies following infection suggests that certain DMTs may alter SARS CoV2-Ab response or persistence.
Insights
People with multiple sclerosis (MS) treated with certain disease-modifying therapies (DMTs) showed a low incidence of COVID-19 antibodies, suggesting DMTs may impact the immune response to SARS-CoV-2 infection.
Area of Science:
- Neurology
- Immunology
- Infectious Diseases
Background:
- The COVID-19 pandemic presented unique safety concerns for individuals with multiple sclerosis (MS).
- This study investigated the immune response to SARS-CoV-2 in MS patients during the early pandemic.
Discussion:
- Observational study conducted at a single MS center.
- Included 48 patients with suspected COVID-19; 17 were tested for antibodies.
- Demographics: average age 49.8 years, 76% female.
Key Insights:
- 65% of patients were on anti-CD20 therapies, 12% were untreated.
- 59% of tested patients were negative for SARS-CoV-2 antibodies.
- Low antibody incidence suggests disease-modifying therapies may affect SARS-CoV-2 antibody response or persistence.
Outlook:
- Further research is needed to understand the long-term implications of DMTs on COVID-19 immunity in MS patients.
- Investigating specific DMTs' impact on antibody durability is crucial.
- This highlights the need for personalized risk assessment and management strategies for MS patients during viral outbreaks.
